Pyros Pharmaceuticals Announces VIGPODER™ (vigabatrin) is Now Available
Pyros Announces Positive Outcome of the Procedure for Approval of VIGZIP
Pyros Pharmaceuticals’ Abstract Accepted for Poster Presentation at the American Epilepsy Society (AES) 2023 Annual Meeting